Jefferies International Reaffirms a “Buy” Rating on Sophos Group Plc (LON:SOPH) and GBX 750.00 Target; Harvard Bioscience (HBIO) Shorts Lowered By 3.41%

Harvard Bioscience, Inc. (NASDAQ:HBIO) Logo

Analysts at Jefferies International have GBX 750.00 price target on Sophos Group Plc (LON:SOPH). Jefferies International’s price target would indicate a potential upside of 57.89% from the company’s previous stock close. The rating was released in a research note on Tuesday morning.

Harvard Bioscience Inc (NASDAQ:HBIO) had a decrease of 3.41% in short interest. HBIO’s SI was 238,100 shares in May as released by FINRA. Its down 3.41% from 246,500 shares previously. With 145,800 avg volume, 2 days are for Harvard Bioscience Inc (NASDAQ:HBIO)’s short sellers to cover HBIO’s short positions. The SI to Harvard Bioscience Inc’s float is 0.81%. The stock decreased 3.00% or $0.15 during the last trading session, reaching $4.85. About 200,456 shares traded or 38.83% up from the average. Harvard Bioscience, Inc. (NASDAQ:HBIO) has risen 87.27% since May 8, 2017 and is uptrending. It has outperformed by 75.72% the S&P500.

Among 12 analysts covering Sophos Group Plc (LON:SOPH), 10 have Buy rating, 1 Sell and 1 Hold. Therefore 83% are positive. Sophos Group Plc has GBX 865 highest and GBX 226 lowest target. GBX 554.50’s average target is 4.82% above currents GBX 529 stock price. Sophos Group Plc had 98 analyst reports since August 7, 2015 according to SRatingsIntel. Liberum Capital maintained the shares of SOPH in report on Wednesday, November 11 with “Buy” rating. The firm has “Buy” rating by Deutsche Bank given on Tuesday, October 31. JP Morgan maintained the stock with “Overweight” rating in Friday, May 27 report. As per Monday, February 15, the company rating was maintained by Peel Hunt. The company was maintained on Thursday, February 8 by Shore Capital. The rating was maintained by Liberum Capital on Monday, January 25 with “Buy”. The firm has “Hold” rating by Numis Securities given on Thursday, May 26. Peel Hunt maintained it with “Buy” rating and GBX 360 target in Tuesday, February 9 report. The firm has “Buy” rating given on Tuesday, September 13 by Deutsche Bank. Peel Hunt maintained Sophos Group plc (LON:SOPH) rating on Tuesday, November 10. Peel Hunt has “Buy” rating and GBX 330 target.

Sophos Group plc, through its subsidiaries, provides cloud-enabled end-user and network security solutions. The company has market cap of 2.48 billion GBP. The firm offers XG Firewall, a next-generation firewall protection for network, users, and applications from new control center; SG UTM, a user interface to protect network and users; Secure Wi-Fi, a wireless access point; Secure Web Gateway for web security; Secure Email Gateway solutions; and Phish Threat, an email phishing test simulation and training product. It currently has negative earnings. It also provides Endpoint Protection, a security solution for users and data; Intercept X, an endpoint security solution; Sophos Mobile, an enterprise mobility management solution; SafeGuard Encryption solution; Server Protection solution; Sophos Home, a protection solution for home computers; and Sophos Central, a synchronized security management solution.

The stock increased 0.38% or GBX 2 during the last trading session, reaching GBX 529. About 240,626 shares traded. Sophos Group plc (LON:SOPH) has 0.00% since May 8, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 3 analysts covering Harvard Bioscience Inc (NASDAQ:HBIO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Harvard Bioscience Inc has $1000 highest and $5.50 lowest target. $7.83’s average target is 61.44% above currents $4.85 stock price. Harvard Bioscience Inc had 4 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Harvard Bioscience, Inc. (NASDAQ:HBIO) earned “Buy” rating by Benchmark on Tuesday, July 28. On Thursday, November 17 the stock rating was initiated by Singular Research with “Buy”.

Investors sentiment increased to 1.32 in Q4 2017. Its up 0.41, from 0.91 in 2017Q3. It increased, as 3 investors sold Harvard Bioscience, Inc. shares while 16 reduced holdings. 8 funds opened positions while 17 raised stakes. 22.13 million shares or 3.01% more from 21.49 million shares in 2017Q3 were reported. The New York-based Comml Bank Of New York Mellon has invested 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Dimensional Fund Advisors Limited Partnership owns 1.77M shares. Moreover, Manufacturers Life Insur The has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 2,095 shares. Earnest Prtn accumulated 2,600 shares. Foundry Partners Ltd Liability Corporation invested in 731,345 shares or 0.1% of the stock. First Manhattan stated it has 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Deutsche Bankshares Ag reported 23,266 shares or 0% of all its holdings. State Street holds 0% or 23,027 shares. Panagora Asset Mngmt stated it has 0% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Woodmont Inv Counsel Ltd Liability Corp holds 176,091 shares or 0.15% of its portfolio. Essex Investment Mgmt Com Llc stated it has 0.23% in Harvard Bioscience, Inc. (NASDAQ:HBIO). Moreover, Pnc Services Gp has 0% invested in Harvard Bioscience, Inc. (NASDAQ:HBIO) for 3,537 shares. California Public Employees Retirement System reported 0% of its portfolio in Harvard Bioscience, Inc. (NASDAQ:HBIO). Bridgeway Capital Mngmt owns 835,917 shares or 0.03% of their US portfolio. Gsa Prtn Llp has invested 0.04% in Harvard Bioscience, Inc. (NASDAQ:HBIO).

Harvard Bioscience, Inc. develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company has market cap of $172.97 million. The firm offers cell and animal physiology products, such as syringe pump and peristaltic pump products, as well as a range of instruments and accessories, including surgical products, infusion systems, microdialysis instruments, behavior research systems, and isolated organ and tissue bath systems, as well as in vivo and in vitro electrophysiology recording, stimulation, and analysis systems for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, Hugo-Sachs, InBreath Bioreactor, MCS, TBSI, and HEKA brands. It currently has negative earnings. It also provides products for molecular biology labs comprising pipettes and pipette tips, gloves, gel electrophoresis equipment and reagents, autoradiography films, thermal cycler accessories and reagents, sample preparation columns, tissue culture products, and general lab equipment and consumables under the Denville Scientific and other brands.

Harvard Bioscience, Inc. (NASDAQ:HBIO) Institutional Positions Chart